e-learning
resources
ERJ
2002
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis
App E.M., Baran D., Dab I., Malfroot A., Coffiner M., Vanderbist F., King M.
Source:
Eur Respir J 2002; 19: 294-302
Journal Issue:
February
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
App E.M., Baran D., Dab I., Malfroot A., Coffiner M., Vanderbist F., King M.. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis. Eur Respir J 2002; 19: 294-302
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
A 62-year-old man with scanty mucoid sputum
Eosinophilic COPD
Related content which might interest you:
Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis
Source: Eur Respir J 2002; 20: 122-126
Year: 2002
RhDNase after airway clearance therapy improves peripheral airway patency in children with cystic fibrosis
Source: Annual Congress 2006 - Cystic fibrosis lung disease: molecules images and drugs
Year: 2006
Lack of therapeutic potential for topical metformin in treatment of airway secretion dehydration in cystic fibrosis
Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease
Year: 2009
Pharmacological treatment of the biochemical defect in cystic fibrosis airways
Source: Eur Respir J 2001; 17: 1314-1321
Year: 2001
Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice
Source: Eur Respir J 2011; 37: 72-78
Year: 2011
Potential therapeutic use of 12-Lipoxygenase inhibitors in the treatment of mucus overproduction in cystic fibrosis
Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease
Year: 2009
Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis
Source: Eur Respir J 2001; 18: 316-322
Year: 2001
Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis
Source: Eur Respir J , 49 (3) 1600987; DOI: 10.1183/13993003.00987-2016
Year: 2017
Pharmacological airway clearance strategies in bronchiectasis
Source: Eur Respir Mon 2011; 52: 239-247
Year: 2011
Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation
Source: Eur Respir J 2011; 38: 1328-1335
Year: 2011
Inhaled heparin in cystic fibrosis
Source: Eur Respir J 2006; 27: 354-358
Year: 2006
Nebulised 7 % hypertonic sodium chloride improves lung function and airway clearance in non cystic fibrosis bronchiectasis
Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management
Year: 2010
Long-term clearance from small airways in patients with cystic fibrosis
Source: Eur Respir J 2005; 25: 317-323
Year: 2005
Possible mechanisms of action of azithromycin in cystic fibrosis
Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle
Year: 2005
Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells
Source: Eur Respir J 2015; 45: 428-439
Year: 2015
Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis},
Source: Eur Respir J 2012; 40: 969-976
Year: 2012
Personalised anti-inflammatory therapy for bronchiectasis and cystic fibrosis: selecting patients for controlled trials of neutrophil elastase inhibition
Source: ERJ Open Res, 5 (1) 00252-2018; 10.1183/23120541.00252-2018
Year: 2019
Long-term efficacy and safety of tobramycin 300mg/4mL nebuliser solution in patients with cystic fibrosis and chronic
Pseudomonas aeruginosa
infection
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis
Year: 2012
Lung function parameters influence serum concentration after antibiotic inhalation in patients with cystic fibrosis
Source: Eur Respir J 2001; 18: Suppl. 33, 537s
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept